Biological variations in plasma VEGF and VEGFR-1 may compromise their biomarker value in colorectal cancer

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 70, Issue 7, 2010, Pages 503-511

  Svendsen, Mads N ^a   Brünner, Nils ^b   Christensen, Ib J ^a   Ytting, Henriette ^a   Bentsen, Camilla ^a   Lomholt, Anne F ^a   Nielsen, Hans J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Biological variation; Blood plasma; Diagnostic marker; EDTA plasma; Vascular endothelial growth factor A; Vascular endothelial growth factor receptor 1

Indexed keywords

BIOLOGICAL MARKER; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; INTESTINE ENDOSCOPY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PRECANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 77958465758     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2010.521254     Document Type: Article

References (38)

1. Risau W. Mechanisms of angiogenesis. Nature 1997;386: 671-674
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257
3. Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996;2:167-168
4. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221-228
5. Hillen F, Griffi oen AW. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007;26: 489-502.
6. Kliche S, Waltenberger J. VEGF receptor signaling and endothelial function. IUBMB Life 2001;52:61-66
7. Ortega N, Hutchings H, Plouet J. Signal relays in the VEGF System. Front Biosci 1999;4:D141-52.
8. Barleon B, Reusch P, Totzke F, Herzog C, Keck C, Martiny-Baron G, Marme D. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 2001;4: 143-154
9. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA, Curiel DT. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998;95:8795-8800
10. Anthony T, Fleming JB, Bieligk SC, Sarosi GA, Kim LT, Gregorcyk SG, Simmang CL, Turnage RH. Postoperative colorectal cancer surveillance. J Am Coll Surg 2000;190: 737-749
11. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in dukes ' B colorectal cancer patients: how much evidence is enough? Ann Oncol 2003;14:1026-1038
12. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55: 3964-3968
13. Papamichael D. Prognostic role of angiogenesis in colorectal cancer. Anticancer Res 2001;21:4349-4353
14. Roumen RM, Slooter GD, Croiset van Uchelen FA, Huib LV. Preoperative serum vascular endothelial growth factor is not a marker for subsequent recurrence during long-term follow- up of colorectal cancer patients. Dis Colon Rectum 2005;48:1070-1075
15. Karayiannakis AJ, Syrigos KN, Zbar A, Baibas N, Polychronidis A, Simopoulos C, Karatzas G. Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery 2002;131:548-555
16. Werther K, Christensen IJ, Nielsen HJ. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 2002;86: 417-423
17. Gonzalez FJ, Quesada AR, Sevilla I, Baca JJ, Medina MA, Amores J, Diaz JM, Rius-Diaz F, Marques E, Alba E. Prognostic value of serum angiogenic activity in colorectal cancer patients. J Cell Mol Med 2007;11:120-128
18. Nakayama Y, Sako T, Shibao K, Okazaki K, Rempo N, Onitsuka K, Minagawa N, Akahane K, Nagashima N, Nagata N, Itoh H. Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer. Anticancer Res 2002;22:2437-2442
19. Tsai WS, Changchien CR, Yeh CY, Chen JS, Tang R, Chiang JM, Hsieh PS, Fan CW, Wang JY. Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer. Dis Colon Rectum 2006;49:883-894
20. Svendsen MN, Werther K, Nielsen HJ, Kristjansen PE. VEGF and tumour angiogenesis. impact of surgery, wound healing, inflammation and blood transfusion. Scand J Gastroenterol 2002;37:373-379
21. Werther K, Christensen IJ, Nielsen HJ. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 2002;62:343-350
22. Svendsen MN, Werther K, Christensen IJ, Basse L, Nielsen HJ. Infl uence of open versus laparoscopically assisted colectomy on soluble vascular endothelial growth factor (SVEGF) and its soluble receptor 1 (SVEGFR1). Inflamm Res 2005;54: 458-463
23. Selheim F, Holmsen H, Vassbotn FS. Identification of functional VEGF receptors on human platelets. FEBS Lett 2002;512:107-110
24. Caine GJ, Lip GY, Blann AD. Platelet-derived VEGF, Flt-1, Angiopoietin-1 and P-Selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. Ann Med 2004;36:273-277
25. de PA, Prevete N, Fiorentino I, Rossi FW, Staibano S, Montuori N, Ragno P, Longobardi A, Liccardo B, Genovese A, Ribatti D, Walls AF, Marone G. Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. J Immunol 2006;177:7322-7331
26. Ancelin M, Chollet-Martin S, Herve MA, Legrand C, El BJ, Perrot-Applanat M. Vascular endothelial growth factor VEGF189 induces human neutrophil chemotaxis in extravascular tissue via an autocrine amplification mechanism. Lab Invest 2004;84:502-512
27. Feistritzer C, Kaneider NC, Sturn DH, Mosheimer BA, Kahler CM, Wiedermann CJ. Expression and function of the vascular endothelial growth factor receptor FLT-1 in human eosinophils. Am J Respir Cell Mol Biol 2004;30:729-735
28. Chin KF, Greenman J, Reusch P, Gardiner E, Marme D, Monson J. Changes in serum soluble VEGFR-1 and Tie-2 receptors in colorectal cancer patients following surgical resections. Anticancer Res 2004;24:2353-2357
29. Kumar H, Heer K, Greenman J, Kerin MJ, Monson JR. Soluble FLT-1 is detectable in the sera of colorectal and breast cancer patients. Anticancer Res 2002;22:1877-1880
30. Chin KF, Greenman J, Reusch P, Gardiner E, Marme D, Monson JR. Vascular endothelial growth factor and soluble tie-2 receptor in colorectal cancer: associations with disease recurrence. Eur J Surg Oncol 2003;29:497-505.
31. Nielsen HJ, Brunner N, Frederiksen C, Lomholt AF, King D, Jorgensen LN, Olsen J, Rahr HB, Thygesen K, Hoyer U, Laurberg S, Christensen IJ. Plasma tissue inhibitor of metalloproteinases- 1 (TIMP-1): a novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian Endoscopy Study Group on Colorectal Cancer Detection. Scand J Gastroenterol 2008;43:242-248
32. Kirkwood TBL. Geometric means and measures of dispersion. Biometrics 1979;35:908-909
33. Berrahmoune H, Lamont JV, Herbeth B, Fitzgerald PS, Visvikis-Siest S. Biological determinants of and reference values for plasma interleukin-8, monocyte chemoattractant protein-1, epidermal growth factor, and vascular endothelial growth factor: results from the STANISLAS cohort. Clin Chem 2006;52:504-510
34. Brostjan C, Bayer A, Zommer A, Gornikiewicz A, Roka S, Benko T, Yaghubian R, Jakesz R, Steger G, Gnant M, Friedl J, Stift A. Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy. Cancer 2003;98: 2291-2301
35. Hetland ML, Christensen IJ, Lottenburger T, Johansen JS, Svendsen MN, Horslev-Petersen K, Nielsen L, Jorgen NH. Circulating VEGF as a biological marker in patients with rheumatoid arthritis? Preanalytical and biological variability in healthy persons and in patients. Dis Markers 2008;24:1-10.
36. Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGFC, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol. 2003;200:183-194
37. Svendsen MN, Lykke J, Werther K, Christensen IJ, Nielsen HJ. Concentrations of VEGF and VEGFR1 in paired tumor arteries and veins in patients with rectal cancer. Oncol Res 2004;14:611-615
38. Henic E, Borgfeldt C, Christensen IJ, Casslen B, Hoyer- Hansen G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res 2008;14:5785-5793